Equillium (NASDAQ:EQ) Insider Sells $632,000.00 in Stock

Equillium, Inc. (NASDAQ:EQ) insider Stephen Connelly sold 200,000 shares of Equillium stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $3.16, for a total value of $632,000.00. Following the transaction, the insider owned 793,000 shares in the company, valued at $2,505,880. This trade represents a 20.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Stephen Connelly also recently made the following trade(s):

• On Friday, June 5th, Stephen Connelly sold 30,975 shares of Equillium stock. The shares were sold at an average price of $2.94, for a total value of $91,066.50.

Equillium Stock Performance

NASDAQ EQ opened at $2.94 on Monday. The business’s fifty day moving average is $2.20 and its 200 day moving average is $1.71. The company has a market capitalization of $185.90 million, a PE ratio of -9.19 and a beta of 1.77. Equillium, Inc. has a fifty-two week low of $0.27 and a fifty-two week high of $3.45.

Equillium (NASDAQ:EQ) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). On average, sell-side analysts forecast that Equillium, Inc. will post -0.24 EPS for the current year.

Institutional Investors Weigh In On Equillium

Several large investors have recently added to or reduced their stakes in EQ. Aberdeen Group plc bought a new stake in Equillium during the third quarter worth approximately $543,000. Vanguard Group Inc. increased its stake in Equillium by 59.4% during the third quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company’s stock worth $1,879,000 after acquiring an additional 489,855 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in Equillium during the third quarter worth approximately $99,000. Two Sigma Investments LP bought a new stake in Equillium during the third quarter worth approximately $190,000. Finally, ADAR1 Capital Management LLC bought a new stake in Equillium during the third quarter worth approximately $7,951,000. 27.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

EQ has been the topic of a number of recent analyst reports. B. Riley Financial initiated coverage on Equillium in a report on Thursday, April 16th. They set a “buy” rating and a $6.00 price target on the stock. Raymond James Financial reissued a “strong-buy” rating and set a $7.00 price target on shares of Equillium in a report on Thursday, May 28th. Zacks Research raised Equillium to a “hold” rating in a report on Thursday, February 26th. Stifel Nicolaus set a $5.00 target price on Equillium in a report on Thursday, May 28th. Finally, Wall Street Zen cut Equillium from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $7.57.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.